Loading viewer...
investor_presentation
Format: PDF investor_presentation
Clinical-stage biotech company developing HADUVIO, an oral dual-acting therapeutic targeting pruritus (itching) and cough through peripheral and central kappa/mu receptor modulation. Presents data from Phase 2 trials in uremic pruritus and prurigo nodolaris, with lead candidates in large-market indications including IPF.
investor_presentation
25 Pages
Tata Consultancy Services
Evergreen Property Partners Modular Housing Investment
investor_presentationinvestor_presentation
45 Pages
Evergreen Property Partners, LLC